Advanced MYCHELANGELO„ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data...
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (Omega), a clinical-stage biotechnology company pioneering the development of a new class of...
MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanismValidation of novel translational assay...
Plus: Trevena’s strategic review for its commercial drug, Algernon’s new focus and Antibe Therapeutics’ clinical hold.
Advanced OTX-2002 in MYCHELANGELO„¢ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patientsEstablished a research collaboration with Novo Nordisk to develop an...
Omega Therapeutics Announces Two Poster Presentations
Omega collaboration will leverage the company™s platform to develop an epigenomic controller as part of a new approach to obesity managementCellarity collaboration will build upon initial work and...
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (Omega), a clinical-stage biotechnology company pioneering the development of a new class of...
CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (œOmega), a clinical-stage biotechnology company pioneering the development of a new class of...
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...